Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BX-001N to Prevent Cardiac Surgery-Associated Acute Kidney Injury
NCT07164833Phase 2Recruiting
- Sponsor
- Bilix
- Start
- Aug 2025
- Primary completion
- Sep 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Brixelle in acute kidney injury (AKI) (4 arms), sponsored by Bilix. Primary endpoints: Neutrophil Gelatinase-Associated Lipocalin at Day 7, Serum Creatinine at Day 7 and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
Brixelle
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07164833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07164833.